Effectiveness of sitagliptin in asian Indian patients with type 2 diabetes-an Indian tertiary diabetes care center experience.

BACKGROUND this study reports on the effectiveness of sitagliptin in Asian Indian type 2 diabetes patients seen at a tertiary diabetes care center who had inadequate glycemic control with oral hypoglycemic agents either alone or in combination, compared to a group of patients who received insulin glargine. PATIENTS AND METHODS patients with type 2 diabetes mellitus (n = 2,817) whose glycemia was not controlled adequately (glycated hemoglobin >6.5%) with oral hypoglycemic agents (either alone or in combination) received oral sitagliptin 100 mg once daily in addition to existing therapy for a period of 24 weeks. Patients who received insulin glargine as add-on therapy (n = 2,743) served as the reference group. Data analysis included glycated hemoglobin, fasting plasma glucose, lipid profile, body weight, and the occurrence of hypoglycemia. RESULTS significant reductions in glycated hemoglobin and fasting plasma glucose values were noted after 24 weeks of additional sitagliptin therapy that were comparable to those with insulin glargine. While sitagliptin addition resulted in a small weight loss (0.3 kg), insulin glargine addition resulted in a weight gain (0.7 kg). The overall incidence of adverse experiences was low and generally mild in both groups. CONCLUSIONS in a large group of Asian Indian type 2 diabetes patients seen at a tertiary diabetes center in whom glycemia was not controlled adequately by oral hypoglycemic agents (either alone or in combination), addition of sitagliptin helped to achieve glycemic control to a similar extent as insulin glargine but with a marginal weight advantage.

[1]  G. Golm,et al.  Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes , 2010, Diabetes, obesity & metabolism.

[2]  P. Kushner,et al.  Type 2 Diabetes Comorbidities and Treatment Challenges: Rationale for DPP-4 Inhibitors , 2010, Postgraduate medicine.

[3]  M. Davies,et al.  Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study , 2010, International journal of clinical practice.

[4]  A. Scheen,et al.  [Sugar: results of a Belgian observational study on the use of sitagliptin in patients with type 2 diabetes]. , 2010, Revue medicale de Liege.

[5]  S. Garg The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review. , 2010, Diabetes technology & therapeutics.

[6]  V. Mohan,et al.  Epidemiology of Cardiovascular Disease in Type 2 Diabetes: The Indian Scenario , 2010, Journal of diabetes science and technology.

[7]  V. Basevi Standards of Medical Care in Diabetes—2010 , 2010, Diabetes Care.

[8]  A. Peters,et al.  Patient and treatment perspectives: Revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk , 2009, Cleveland Clinic Journal of Medicine.

[9]  R. Henry,et al.  Pharmacotherapy of hyperglycemia , 2009, Expert opinion on pharmacotherapy.

[10]  Bryan R Luce,et al.  Rethinking Randomized Clinical Trials for Comparative Effectiveness Research: The Need for Transformational Change , 2009, Annals of Internal Medicine.

[11]  D. Riche,et al.  Impact of Sitagliptin on Markers of &bgr;-cell Function: A Meta-Analysis , 2009, The American journal of the medical sciences.

[12]  Ambady Ramachandran,et al.  Pioglitazone does not enhance the effectiveness of lifestyle modification in preventing conversion of impaired glucose tolerance to diabetes in Asian Indians: results of the Indian Diabetes Prevention Programme-2 (IDPP-2) , 2009, Diabetologia.

[13]  Melanie J. Davies,et al.  Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study , 2009, Current medical research and opinion.

[14]  V. Mohan,et al.  Prevalence and significance of generalized and central body obesity in an urban Asian Indian population in Chennai, India (CURES: 47) , 2009, European Journal of Clinical Nutrition.

[15]  M. Davies,et al.  Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes * , 2008, Diabetes, obesity & metabolism.

[16]  E. Liberopoulos,et al.  Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes , 2008, Expert opinion on pharmacotherapy.

[17]  P. Stein,et al.  Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. , 2008, Diabetes research and clinical practice.

[18]  F. Pi‐Sunyer,et al.  The Effects of Pharmacologic Agents for Type 2 Diabetes Mellitus on Body Weight , 2008, Postgraduate medicine.

[19]  K. Hermansen,et al.  Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin , 2007, Diabetes, obesity & metabolism.

[20]  S. Yusuf,et al.  The DREAM trial – Authors' reply , 2006, The Lancet.

[21]  P. Stein,et al.  Efficacy and tolerability of the dipeptidyl peptidase‐4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes , 2006, International journal of clinical practice.

[22]  Ronald Brazg,et al.  Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. , 2006, Clinical therapeutics.

[23]  C. Snehalatha,et al.  The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1) , 2006, Diabetologia.

[24]  R. Glasgow,et al.  A practical randomized trial to improve diabetes care , 2004, Journal of General Internal Medicine.

[25]  Ambady Ramachandran,et al.  Low risk threshold for acquired diabetogenic factors in Asian Indians. , 2004, Diabetes research and clinical practice.

[26]  M. Riddle,et al.  Timely initiation of basal insulin. , 2004, The American journal of medicine.

[27]  P. Cryer,et al.  Hypoglycaemia: The limiting factor in the glycaemic management of Type I and Type II Diabetes* , 2002, Diabetologia.

[28]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002, The New England journal of medicine.

[29]  M. Engelgau,et al.  Translation research for chronic disease: the case of diabetes. , 2000, Diabetes care.

[30]  O. Pedersen,et al.  Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study , 1999, The Lancet.

[31]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[32]  J. Shaw,et al.  Global estimates of the prevalence of diabetes for 2010 and 2030. , 2010, Diabetes research and clinical practice.

[33]  V. Mohan,et al.  Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. , 2009, Diabetes research and clinical practice.